Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Programmed death (PD) pathway antibodies are revolutionizing cancer immunotherapy.
• Five antibodies targeting PD-1/PD-L1 have received regulatory approval.
• The clinical application of these immunotherapies is rapidly expanding.

Purpose of the Study:

• To review recent developments in clinical trials involving PD-1 and PD-L1 antibodies for cancer immunotherapy.
• To highlight the expanding role of PD-1/PD-L1 antibodies in combination therapies.

Main Methods:

• Review of recent clinical trial data for PD-1 and PD-L1 antibodies.
• Analysis of combination strategies including chemotherapy and small molecule inhibitors.

Main Results:

• Approved combination therapy: pembrolizumab with carboplatin and pemetrexed for metastatic non-squamous non-small cell lung cancer.
• Ongoing clinical trials investigate combinations of PD-1/PD-L1 antibodies with tyrosine kinase inhibitors and IDO inhibitors.

Conclusions:

• PD-1/PD-L1 antibodies represent a significant advancement in cancer immunotherapy.
• Combination strategies are crucial for expanding the efficacy and application of PD-1/PD-L1 blockade.